Pharma Journalist -

Roche announced positive results from the Phase III IMvigor011 study evaluating Tecentriq® (atezolizumab) as an adjuvant treatment for muscle-invasive bladder cancer (MIBC) in patients…
Read More...

GSK plc announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of a new prefilled…
Read More...

SAE Media Group unveils the full agenda for AI in Drug Discovery Conference 400 ticket saving ends 7 November 2025. 2026, highlighting the technologies and strategies driving …
Read More...

Glaukos Corporation announced that the U.S. Food and Drug Administration (FDA) has approved its novel corneal cross-linking therapy, Epioxa™ (Epioxa™ HD / Epioxa™), marking a major…
Read More...

Roche has announced positive phase III results from its IMvigor011 study, showing that Tecentriq® (atezolizumab) significantly improves survival outcomes in patients with…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who…
Read More...

H. Lundbeck A/S and Contera Pharma have announced a strategic research collaboration aimed at developing RNA-based medicines for serious neurological disorders with high unmet medical…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who…
Read More...

The Global Fund to Fight AIDS, Tuberculosis and Malaria has welcomed a new £6 million investment from GSK and its HIV specialist company ViiV Healthcare to strengthen community-led…
Read More...

Roche announced positive Phase III results from its evERA Breast Cancer study, showing that the investigational drug giredestrant, when combined with everolimus, significantly improved…
Read More...